Victory Capital Management
KRYS icon

Victory Capital Management’s Krystal Biotech KRYS Stock Holding History

Victory Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
44,935
+4,220
+10% +$1.26M 0.01% 963
2026
Q1 		$10.5M Buy
40,715
+14,254
+54% +$3.79M 0.01% 1064
2025
Q4 		$6.52M Sell
26,461
-28,355
-52% -$5.97M ﹤0.01% 1213
2025
Q3 		$9.68M Sell
54,816
-25,307
-32% -$3.79M 0.01% 1119
2025
Q2 		$11M Buy
80,123
+7,308
+10% +$1.07M 0.01% 1079
2025
Q1 		$13.1M Sell
72,815
-8,513
-10% -$1.43M 0.01% 952
2024
Q4 		$12.7M Sell
81,328
-16,957
-17% -$3.01M 0.01% 996
2024
Q3 		$17.9M Sell
98,285
-45,580
-32% -$8.79M 0.02% 887
2024
Q2 		$26.4M Buy
143,865
+9,045
+7% +$1.52M 0.03% 706
2024
Q1 		$24M Sell
134,820
-38,059
-22% -$5.29M 0.02% 748
2023
Q4 		$21.4M Sell
172,879
-36,608
-17% -$4.06M 0.02% 751
2023
Q3 		$24.3M Buy
209,487
+12,448
+6% +$1.52M 0.03% 671
2023
Q2 		$23.1M Sell
197,039
-15,091
-7% -$1.54M 0.03% 717
2023
Q1 		$17M Sell
212,130
-127,201
-37% -$9.99M 0.02% 845
2022
Q4 		$26.9M Buy
339,331
+35,732
+12% +$2.65M 0.03% 668
2022
Q3 		$21.2M Buy
303,599
+276,251
+1,010% +$20M 0.02% 784
2022
Q2 		$1.79M Buy
+27,348
New +$1.7M ﹤0.01% 1504
2022
Q1 		– Sell
-2,864
Closed -$200K – 2771
2021
Q4 		$200K Buy
+2,864
New +$167K ﹤0.01% 2486
2021
Q2 		– Sell
-2,776
Closed -$214K – 2790
2021
Q1 		$214K Buy
+2,776
New +$202K ﹤0.01% 2512
2020
Q4 		– Sell
-524,144
Closed -$22.6M – 2564
2020
Q3 		$22.6M Buy
524,144
+246,047
+88% +$10.7M 0.03% 739
2020
Q2 		$11.5M Buy
278,097
+276,508
+17,401% +$13.3M 0.02% 978
2020
Q1 		$69K Sell
1,589
-515
-24% -$26.9K ﹤0.01% 2424
2019
Q4 		$117K Buy
2,104
+365
+21% +$17.9K ﹤0.01% 2491
2019
Q3 		$60K Buy
+1,739
New +$77.7K ﹤0.01% 2603

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Victory Capital Management's KRYS Position: Q2 2026 in Review

Victory Capital Management increased its Krystal Biotech (KRYS) stake by 10% in Q2 2026, buying an estimated $1.26M and bringing the position to 44,935 shares worth $16.7M. The position accounts for 0.01% of the portfolio, ranked #963.

Victory Capital Management first reported a position in KRYS in Q3 2019 and has held it in 24 quarters since. The position peaked at $26.9M in Q4 2022. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Victory Capital Management held 44,935 shares of Krystal Biotech worth $16.7M as of Q2 2026.
  • Victory Capital Management bought 4,220 Krystal Biotech shares in Q2 2026, an estimated $1.26M.
  • Krystal Biotech made up 0.01% of Victory Capital Management's portfolio in Q2 2026, its #963 holding.
  • Victory Capital Management first reported a position in Krystal Biotech in Q3 2019 and has held it in 24 quarters since.
  • Victory Capital Management's Krystal Biotech position peaked at $26.9M in Q4 2022.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.